Related Experiment Video
Updated: Aug 9, 2026
12:22
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Chemotherapy for renal cell carcinoma
1Department of Hematology/Oncology/Immunology, Eberhard-Karls-University, Tuebingen, Germany.
Anticancer Research
|June 12, 1999
Summary
Chemotherapy offers limited benefit for metastatic renal cell carcinoma, with vinblastine as the current standard. New agents targeting mechanisms beyond multidrug resistance are needed for advanced disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Renal cell carcinoma (RCC) is largely resistant to chemotherapy.
- Common cytotoxic agents show only marginal response rates in RCC patients.
Purpose of the Study:
- To review the efficacy of current and emerging chemotherapy agents for metastatic renal cell carcinoma.
- To assess the role of multidrug resistance (MDR) mechanisms in RCC chemotherapy resistance.
Main Methods:
- Review of clinical trials and published data on chemotherapy agents for metastatic RCC.
- Analysis of response rates and survival benefits associated with various chemotherapeutic regimens.
- Evaluation of studies investigating MDR inhibitors in combination with chemotherapy.
Main Results:
- Vinblastine demonstrates a consistent 6-9% objective response rate.
- 5-fluorouracil and Floxuridin (FUDR) show 5-8% response rates, with chronomodulation offering slight improvement.
- Newer agents, taxanes, gemcitabine, and MDR-inhibitor combinations have shown limited efficacy.
Conclusions:
- Chemotherapy has a restricted role in managing metastatic renal cell carcinoma.
- Vinblastine remains the standard treatment despite its limitations.
- Further research into novel agents independent of MDR mechanisms is crucial for improving palliative care in advanced RCC.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...